Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer. The ACET news feed on Stock Titan aggregates company-issued updates, SEC-linked announcements, and other coverage related to Adicet’s clinical programs, capital markets activity, and regulatory interactions.
Investors and followers of Adicet Bio can use this page to review news on its lead program, prulacabtagene leucel (prula-cel, formerly ADI-001), an investigational allogeneic gamma delta CAR T therapy targeting B cells via an anti-CD20 CAR. Company releases have highlighted Phase 1 data in lupus nephritis and systemic lupus erythematosus, enrollment across additional autoimmune indications such as systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA associated vasculitis and treatment-refractory rheumatoid arthritis, and regulatory designations including Fast Track status for several of these conditions.
The ACET news stream also reflects Adicet’s oncology work, including updates on ADI-212, a next-generation, gene-edited and armored gamma delta CAR T candidate targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Preclinical data presentations, plans for regulatory filings, and development timelines are typically communicated through press releases and associated 8-K filings.
Beyond clinical and scientific developments, Adicet Bio’s news includes information on registered direct offerings of common stock and pre-funded warrants, reverse stock split decisions, Nasdaq listing status notices, workforce and pipeline prioritization actions, and participation in healthcare conferences. By reviewing this curated ACET news page, readers can follow how Adicet reports progress in its autoimmune and oncology pipelines, how it manages its capital structure, and how key milestones are communicated through official channels.
Adicet Bio (Nasdaq: ACET) reported positive preliminary Phase 1 data for ADI-001 in lupus nephritis (LN) and systemic lupus erythematosus (SLE) as of the August 31, 2025 data cut-off. All seven evaluable patients (five LN, two SLE) showed rapid, sustained SLEDAI-2K and PGA score reductions and immune reset signals after a single dose. All five LN patients achieved renal responses (three complete responses with DORIS remissions, two partial responses), with responses ongoing. ADI-001 was generally well tolerated (no SAEs, no ICANS, two Grade 1 CRS, one Grade 1 infection). More than 25 sites are open; Adicet plans an FDA meeting in 1Q/2026 and anticipates a pivotal study start in 2Q/2026.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech company focused on allogeneic gamma delta T cell therapies, has granted an inducement award to a new employee. The award consists of non-qualified stock options to purchase 9,800 shares at an exercise price of $0.81 per share.
The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments. The award was granted under Adicet's 2022 Inducement Plan and approved by the compensation committee as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's President and CEO, Chen Schor, will deliver a presentation on September 8, 2025, at 4:30 p.m. ET in New York.
Investors can access the live audio webcast through Adicet Bio's website, with a replay available for 30 days after the presentation.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to two new employees in August 2025. The awards consist of non-qualified stock options to purchase 84,000 shares of common stock at $0.72 per share.
The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments. These awards were granted under Adicet's 2022 Inducement Plan as approved by the compensation committee, following Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) reported Q2 2025 financial results and provided significant updates on its clinical programs. The company is actively enrolling patients in its Phase 1 clinical trial of ADI-001 for multiple autoimmune diseases, including lupus nephritis, systemic lupus erythematosus, and systemic sclerosis, with preliminary data expected in 2H/2025.
The company is prioritizing the development of ADI-212, a next-generation gene-edited therapy for prostate cancer, with regulatory filing expected in Q1 2026. As part of strategic pipeline prioritization, Adicet discontinued ADI-270 development and reduced its workforce by 30%. Financial results showed a net loss of $31.2 million for Q2 2025, with cash position of $125.0 million expected to fund operations into Q4 2026.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies, announced its participation in the 45th Annual Canaccord Genuity Growth Conference. Chen Schor, President and CEO, will engage in a fireside chat on August 12, 2025, at 1:30 p.m. ET in Boston.
The presentation will be accessible via live audio webcast through Adicet Bio's investor relations website, with a replay available for 30 days after the event.
Adicet Bio (Nasdaq: ACET) has reached a significant milestone in its Phase 1 clinical trial of ADI-001 for autoimmune diseases, announcing the dosing of the first systemic sclerosis (SSc) patient in the trial's second cohort. The study is actively enrolling patients across three conditions: lupus nephritis (LN), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc).
The company's Chief Medical Officer, Dr. Julie Maltzman, highlighted the critical unmet need for effective treatments in autoimmune diseases and expressed optimism about ADI-001's potential therapeutic benefits. Preliminary clinical data from this Phase 1 trial is expected in the second half of 2025.
Adicet Bio (NASDAQ: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO, Chen Schor, will engage in a fireside chat on June 4, 2025, at 4:20 p.m. ET in New York. The presentation will be accessible via live audio webcast on Adicet Bio's website, with a replay available for 30 days afterward.
Adicet Bio has announced new inducement grants under Nasdaq Listing Rule 5635(c)(4). The clinical-stage biotech company, focused on developing allogeneic gamma delta T cell therapies, granted stock options to three new employees hired in April 2025.
The key details of the grants include:
- Total shares: 206,800 of common stock
- Exercise price: $0.66 per share
- Vesting schedule: 25% after one year, remaining 75% over 36 monthly installments
- Full vesting period: 4 years
These awards were granted through Adicet's 2022 Inducement Plan, which was amended in January 2023. The compensation committee approved these grants as material inducement for new employees, complying with Nasdaq regulations.